文献速递基础与转化研究临床试验与 GCP

基因型指导口服P2Y12抑制剂选择对PCI后缺血结局的影响:TAILOR-PCI随机临床试验

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

TAILOR-PCI是一项开放标签随机临床试验,纳入5302例接受PCI的急性冠脉综合征或稳定性冠心病患者,比较基因型指导(CYP2C19 LOF携带者用替格瑞洛,非携带者用氯吡格雷)与常规氯吡格雷治疗对12个月缺血结局的影响。

要点

  • CYP2C19 LOF携带者PCI后基因型指导P2Y12抑制剂选择未显著降低12个月主要缺血终点。
  • 基因型指导组与常规组大出血或小出血发生率无显著差异。

核心结论

  • 在CYP2C19 LOF携带者中,基因型指导口服P2Y12抑制剂选择相比常规氯吡格雷治疗,12个月主要复合缺血终点无统计学显著差异。

研究设计与样本

  • 基因型指导组2652例接受即时基因分型,CYP2C19 LOF携带者用替格瑞洛,非携带者用氯吡格雷;常规组2650例用氯吡格雷,12个月后基因分型。
  • 主要分析在CYP2C19 LOF变异患者中进行,次要分析包括所有随机患者;试验有85%把握度检测最小风险比0.50。

主要发现

  • 在1849例CYP2C19 LOF携带者中,基因型指导组903例中764例(85%)接受替格瑞洛,常规组946例中932例(99%)接受氯吡格雷。
  • 11个预设次要终点均无显著差异。

临床怎么用

  • 对于接受PCI的CYP2C19 LOF携带者,即时基因分型指导P2Y12抑制剂选择未显示显著优于常规氯吡格雷治疗的缺血获益。

局限性

  • 主要分析未达到统计学显著性,试验仅有力检测HR 0.50的治疗效应。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: After percutaneous coronary intervention (PCI), patients with CYP2C19*2 or *3 loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic events. Whether genotype-guided selection of oral P2Y12 inhibitor therapy improves ischemic outcomes is unknown. OBJECTIVE: To determine the effect of a genotype-guided oral P2Y12 inhibitor strategy on ischemic outcomes in CYP2C19 LOF carriers after PCI. DESIGN, SETTING, AND PARTICIPANTS: Open-label randomized clinical trial of 5302 patients undergoing PCI for acute coronary syndromes (ACS) or stable coronary artery disease (CAD). Patients were enrolled at 40 centers in the US, Canada, South Korea, and Mexico from May 2013 through October 2018; final date of follow-up was October 2019. INTERVENTIONS: Patients randomized to the genotype-guided group (n = 2652) underwent point-of-care genotyping. CYP2C19 LOF carriers were prescribed ticagrelor and noncarriers clopidogrel. Patients randomized to the conventional group (n = 2650) were prescribed clopidogrel and underwent genotyping after 12 months. MAIN OUTCOMES AND MEASURES: The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia at 12 months. A secondary end point was major or minor bleeding at 12 months. The primary analysis was in patients with CYP2C19 LOF variants, and secondary analysis included all randomized patients. The trial had 85% power to detect a minimum hazard ratio of 0.50. RESULTS: Among 5302 patients randomized (median age, 62 years; 25% women), 82% had ACS and 18% had stable CAD; 94% completed the trial. Of 1849 with CYP2C19 LOF variants, 764 of 903 (85%) assigned to genotype-guided therapy received ticagrelor, and 932 of 946 (99%) assigned to conventional therapy received clopidogrel. The primary end point occurred in 35 of 903 CYP2C19 LOF carriers (4.0%) in the genotype-guided therapy group and 54 of 946 (5.9%) in the conventional therapy group at 12 months (hazard ratio [HR], 0.66 [95% CI, 0.43-1.02]; P = .06). None of the 11 prespecified secondary end points showed significant differences, including major or minor bleeding in CYP2C19 LOF carriers in the genotype-guided group (1.9%) vs the conventional therapy group (1.6%) at 12 months (HR, 1.22 [95% CI, 0.60-2.51]; P = .58). Among all randomized patients, the primary end point occurred in 113 of 2641 (4.4%) in the genotype-guided group and 135 of 2635 (5.3%) in the conventional group (HR, 0.84 [95% CI, 0.65-1.07]; P = .16). CONCLUSIONS AND RELEVANCE: Among CYP2C19 LOF carriers with ACS and stable CAD undergoing PCI, genotype-guided selection of an oral P2Y12 inhibitor, compared with conventional clopidogrel therapy without point-of-care genotyping, resulted in no statistically significant difference in a composite end point of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia based on the prespecified analysis plan and the treatment effect that the study was powered to detect at 12 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01742117.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Pereira NL, Farkouh ME, So D, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. 2020. PMID: 32840598. doi:10.1001/jama.2020.12443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。